Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Halia Therapeutics Inc. manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These active matters are distributed across 3 distinct examiners and 3 distinct art units.
JOHN S KENYON is the busiest examiner for the portfolio. This examiner is currently overseeing 1 pending office action, representing 1 of the 3 total pending actions currently active for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KENYON, JOHN S | 1 | 79.7% | +18.2% |
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| VAJDA, KRISTIN ANN | 1 | 83.8% | +11.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262787 | NEK7 INHIBITORS | VAJDA, KRISTIN ANN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699841 | TYRO3 INHIBITORS | KENYON, JOHN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699841 | TYRO3 INHIBITORS | KENYON, JOHN S | — |
| 18262787 | NEK7 INHIBITORS | VAJDA, KRISTIN ANN | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1699 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699841 | TYRO3 INHIBITORS | KENYON, JOHN S | 1625 | §102§112 | Non-Final OA | — | Pending | Apr 09, 2024 |
| 18694836 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | OTTON, ALICIA L | 1699 | §112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18262787 | NEK7 INHIBITORS | VAJDA, KRISTIN ANN | 1622 | §112 | Non-Final OA | — | Pending | Jul 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHalia Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
John S Kenyon has the most, with 1 of Halia Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
